Key Takeaway
Ozempic and Wegovy both contain semaglutide, but they're approved for different purposes. Learn which one is right for your weight loss goals in comparison.
Ozempic and Wegovy contain the exact same active ingredient, semaglutide, but Wegovy is FDA-approved specifically for weight management at a higher maximum dose, making it the better choice if weight loss is your primary goal.
If you have been researching GLP-1 medications, you have probably noticed that Ozempic and Wegovy come up constantly. They're made by the same manufacturer (Novo Nordisk), contain the same molecule, and work through the same biological pathways. So why do two separate products exist, and does it actually matter which one you use?
This comparison matters because Google results and social posts often flatten these drugs into the same thing. They are not the same product, even though both use semaglutide. The differences that matter most are indication, dose ceiling, insurance behavior, and the strength of the weight-loss data.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA-Approved For | Type 2 diabetes | Chronic weight management |
| Maximum Dose | 2 mg/week | 2.4 mg/week |
| Administration | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Titration Schedule | 4 dose levels over 8+ weeks | 5 dose levels over 16-20 weeks |
| Average Weight Loss | ~10-14% of body weight | ~15-17% of body weight |
| List Price (monthly) | $900-$1,000/mo (brand) | $1,300-$1,400/mo (brand) |
| Manufacturer | Novo Nordisk | Novo Nordisk |
How Ozempic Works
GLP-1 Mechanism of Action
Ozempic is a GLP-1 receptor agonist that was approved by the FDA in 2017 for the treatment of type 2 diabetes. It mimics a natural gut hormone called glucagon-like peptide-1, which your body releases after eating. This hormone tells your pancreas to produce more insulin when blood sugar is high, slows down how quickly food leaves your stomach, and sends satiety signals to your brain.
The result for most patients is better blood sugar control and, as a notable side benefit, significant weight loss. Ozempic is available in doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg, administered as a once-weekly injection. Patients typically start at the lowest dose and work their way up over several weeks to minimize gastrointestinal side effects. If you're curious how semaglutide stacks up against newer dual-agonist options, see our semaglutide vs tirzepatide comparison.
FDA Approval and Off-Label Use
Many physicians prescribe Ozempic off-label for weight loss in patients who do not have type 2 diabetes. That is legal and common in medicine, but it often creates insurance friction. Because Ozempic is approved for type 2 diabetes, some plans deny coverage when the goal is weight management alone.
How Wegovy Works
Higher Dose for Weight Loss
Wegovy received FDA approval in June 2021 specifically for chronic weight management. It uses the same semaglutide molecule as Ozempic but reaches a higher maximum dose of 2.4 mg per week. Wegovy is approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. You can check your eligibility with our BMI calculator. For a complete cost breakdown, see our cheapest semaglutide options. For a complete cost breakdown, see our affordable GLP-1 options.
The titration schedule for Wegovy is more gradual than Ozempic. Patients move through five dose levels (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg) over a period of 16 to 20 weeks. This slower ramp-up was designed to reduce the frequency and severity of nausea and other GI side effects that are common when starting semaglutide.
Cardiovascular Benefits (SELECT Trial[2])
Beyond weight loss, Wegovy also received FDA approval in March 2024 for reducing cardiovascular risk in overweight and obese adults, based on results from the SELECT trial. This landmark study demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) in patients taking semaglutide 2.4 mg compared to placebo. This cardiovascular indication is unique to Wegovy and doesn't apply to Ozempic, making it a particularly strong option for patients with improved heart disease risk. For a comparison with another weight-loss medication that has cardiovascular[2] data, see our Wegovy vs Zepbound breakdown.
Efficacy Comparison: Weight Loss Results
STEP Trial Results
The clinical data favors Wegovy for weight loss, which makes sense given its higher maximum dose.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation from a licensed physician.
Take the Assessment →In the STEP 1 trial, patients taking Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Some participants lost over 20% of their starting weight. The STEP program (which included multiple trials across different patient populations) consistently showed weight loss in the 12-17% range. For visual context on what these results look like in practice, our before-and-after guide covers real-world transformations on GLP-1 medications.
SUSTAIN Trial Data
Ozempic's weight loss data comes primarily from the SUSTAIN trials, which were designed to measure blood sugar control rather than weight loss. In SUSTAIN 1 through 5, patients on Ozempic 1 mg typically lost 10-14 lbs over 30 weeks. The higher 2 mg dose, studied in SUSTAIN FORTE, showed greater weight loss, though still generally less than what Wegovy achieves at its 2.4 mg maintenance dose.
Real-World Comparison
If maximum weight loss is the goal, Wegovy's higher dose ceiling gives it a clear edge. But many patients do achieve meaningful weight loss on Ozempic, especially when combined with diet and lifestyle changes. Real-world outcomes can vary from clinical trial averages depending on adherence, diet, physical activity, and individual metabolic factors. For patients who want to explore alternatives beyond semaglutide, our Ozempic vs Zepbound comparison covers how tirzepatide stacks up.
Side Effects: What to Expect
Common GI Side Effects
Because Ozempic and Wegovy contain the same active ingredient, semaglutide, their side effect profiles are very similar. The most common side effects are gastrointestinal:
- Nausea (reported in 20-44% of patients)
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Headache
- Fatigue
These side effects are usually worst during the titration phase and tend to improve as your body adjusts. Wegovy's more gradual titration schedule was specifically designed to ease patients through this adjustment period.
Serious Risks
Serious but rare side effects for both medications include pancreatitis, gallbladder problems, kidney injury, and allergic reactions. Both carry a boxed warning about the risk of thyroid C-cell tumors, based on animal studies. Neither medication should be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Tolerability Comparison
In clinical trials, discontinuation rates due to adverse events were slightly higher for Wegovy than for Ozempic, likely because Wegovy reaches the higher maintenance dose. Most side effects cluster during dose escalation.
Cost Comparison
Brand-Name Pricing
Cost is often the deciding factor between Ozempic and Wegovy, and the space here is complicated.
The list price for Ozempic is approximately $900-$1,000 per month. Wegovy's list price runs approximately $1,300-$1,400 per month. But what you actually pay depends heavily on your insurance plan, manufacturer savings programs, and pharmacy. As of 2026, Novo Nordisk offers savings cards for both medications that can reduce out-of-pocket costs for commercially insured patients.
Insurance Coverage Differences
Insurance coverage for Wegovy has improved since its launch but remains inconsistent. Many plans cover Ozempic more readily because it has a diabetes indication, and insurers have historically been more willing to pay for diabetes medications than weight-management drugs. Some patients and their doctors use Ozempic off-label for weight loss specifically because it's easier to get covered. Medicare Part D began covering Wegovy in 2026 for patients with established cardiovascular disease, which expanded access for a significant patient population.
Compounded Semaglutide Options
For patients without insurance coverage, the real-world decision often becomes whether to pay cash for brand-name semaglutide or consider a lower-cost alternative program. But that question is separate from the Ozempic versus Wegovy comparison itself, and buyers should be careful with marketing that implies sameness or generic equivalence where none exists.
Who Is Ozempic Best For?
Ozempic may be the better choice if you:
- Have type 2 diabetes and want to manage both blood sugar and weight
- Have insurance that covers Ozempic but not Wegovy
- Are looking for a lower maintenance dose of semaglutide
- Want a medication with a longer track record (approved since 2017)
Who Is Wegovy Best For?
Wegovy may be the better choice if you:
- Want to maximize weight loss and your primary goal isn't diabetes management
- Have a BMI of 30+ or 27+ with weight-related health conditions
- Want an FDA-approved weight loss medication (not off-label use)
- Are concerned about cardiovascular risk and want the additional heart benefit demonstrated in the SELECT trial
- Have insurance that specifically covers Wegovy for weight management
Can You Switch Between Ozempic and Wegovy?
Yes, switching between Ozempic and Wegovy is generally straightforward because they contain the same molecule. Your doctor can transition you at an equivalent dose without needing to re-titrate from scratch. For example, a patient on Ozempic 1 mg could move to Wegovy 1 mg and then continue titrating up to 1.7 mg and eventually 2.4 mg.
The most common reason patients switch from Ozempic to Wegovy is to access the higher 2.4 mg dose. The most common reason for switching the other direction is insurance coverage or cost. If you're considering alternatives outside the semaglutide family altogether, our GLP-1 hub covers all available options.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Is Ozempic and Wegovy the same thing?
They contain the same active ingredient, semaglutide, and work through the same biological mechanism, but they are different FDA-approved products. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management. Wegovy also reaches a higher maximum dose, 2.4 mg versus 2 mg, and has an additional cardiovascular-risk indication.
Can I switch from Ozempic to Wegovy?
Yes. Because both medications contain semaglutide, your doctor can transition you at an equivalent dose without restarting the titration process. Most patients switch to access Wegovy's higher 2.4 mg maintenance dose for greater weight loss. Your physician will determine the safest transition approach based on your current dose and response.
Which is better for weight loss, Ozempic or Wegovy?
Clinical trial data favors Wegovy. The STEP 1 trial showed an average weight loss of 14.9% with Wegovy 2.4 mg over 68 weeks, while Ozempic's SUSTAIN trials demonstrated losses of roughly 10-14 lbs at the 1 mg dose over 30 weeks. The difference is largely due to Wegovy's higher maximum dose. But individual results vary, and many patients achieve meaningful weight loss on Ozempic as well.
Does insurance cover Wegovy?
Coverage has expanded in 2026 but remains plan-dependent. Medicare Part D now covers Wegovy for some patients with established cardiovascular disease. Many commercial plans still require prior authorization with documented BMI and comorbidities.
Can I use Ozempic for weight loss if I don't have diabetes?
Yes, many doctors prescribe Ozempic off-label for weight loss. This is legal medical practice. But your insurance may not cover it for that purpose because Ozempic's FDA approval is for type 2 diabetes.
Which one causes fewer side effects?
Side effects are similar for both since they use the same molecule. The most common issues are gastrointestinal: nausea, diarrhea, vomiting, and constipation. Wegovy's longer titration schedule may help reduce early GI side effects, but at its higher maintenance dose, the overall side effect burden is comparable. Discontinuation rates due to adverse events are slightly higher for Wegovy, likely reflecting the higher dose.
How long do I need to take Ozempic or Wegovy?
Both medications are intended for long-term use. Clinical studies show that many patients regain weight after stopping semaglutide, which is why prescribers usually frame obesity treatment as long-term management rather than a short course.
How does semaglutide compare to tirzepatide (Zepbound)?
Tirzepatide (marketed as Zepbound for weight loss and Mounjaro for diabetes) is a dual GIP/GLP-1 receptor agonist, while semaglutide targets only GLP-1. Head-to-head data is limited, but clinical trials suggest tirzepatide may produce slightly greater average weight loss. Both medication classes are highly effective. Read our full semaglutide vs tirzepatide comparison for a detailed breakdown.
If you are still deciding between semaglutide options, our semaglutide vs tirzepatide comparison and semaglutide guide are the next pages worth reading.